2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

654. Multiple Myeloma: Pharmacologic Therapies: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Measurable Residual Disease, Research, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

4022 Maintenance therapy with belantamab, pomalidomide and dexamethasone in high-risk myeloma patients: A Phase 2 study with a safety run-in

Ajay K Nooka, MD, MPH, Nisha Joseph, MD2, Richa Parikh, MD3, Vikas Gupta, MD, PhD4, Craig Hofmeister, MD, MPH5, Nishi Shah, MD, MPH6, Charise Gleason, MD7, Danielle Roberts, MD8, Sara Ann Scott, PharmD, BCOP9, Joel Andrews, MD10, Manali Rupji, MS11, Robert Mina12, Jonathan L Kaufman, MD13, Sagar Lonial, MD, FACP14
1 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
2 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
3 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
4 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
5 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
6 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
7 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
8 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
9 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
10 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
11 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
12 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
13 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
14 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

Maintenance Therapy with Belantamab, Pomalidomide and Dexamethasone in High-risk Myeloma Patients: A Phase 2 Study with a Safety Run-in

Introduction: Disease control among high-risk myeloma patients with combination maintenance strategies have resulted in improved outcomes. We have evaluated the safety and efficacy of the combination of belantamab (BCMA ADC) with pomalidomide (IMiD agent) and dexamethasone (steroid) as maintenance strategy among high-risk myeloma patients (NCT05208307). 

Methods: Newly diagnosed high-risk myeloma pts that have achieved ≥PR post-ASCT were included. High-risk myeloma was defined by the presence of t(4;14), t(14;16), del17p in the first 30 patients. An expanded cohort of another 30 patients qualifying for the definition of IMS-IMWG high risk were planned to be enrolled. Currently enrolment is ongoing with 43 patients enrolled. Each cycle is 28 days. Belantamab 1.9 mg/m2 intravenously (IV) was given every 56 days and pomalidomide 4 mg PO on days 1 to 21 and dexamethasone 40 mg PO weekly. After safety run in was completed, belantamab at a dose of 1.9 mg/kg is administered every 12 weeks, after the first 2 doses received 8 weeks apart (56 days). Ophthalmological evaluations happen per the belantamab dosing schedule. Data cut off is June 30th 2026.

Results:  After a median follow up of 12 months from study entry, only one of the 43 evaluable patients for efficacy had progressed. Unfortunately, one patient died due to non-relapse mortality from a colonic volvulus. When patients receive belantamab 1.9 mg/kg every 12 weeks, there were a total of 9 grade 3 adverse events (AEs) reported of which only one event of grade 3 keratitis in one single patient was observed. Pneumonia, (N=2), febrile neutropenia (N=1), hypoxia (N=1), arrhythmia (N=1), fatigue (N=1), gram positive bacteremia (N=1), sigmoid diverticulitis (N=1) were other serious AEs reported. At data cut-off, all 38 pts were still receiving treatment.


Conclusions: Among patients with high-risk myeloma, BPd maintenance with extended dosing schedule of belantamab 1.9 mg/kg every 12 weeks is not associated with higher grade toxicities and had proven efficacy in this setting.  The current study is continuing to enroll high risk patients per the new IMS-IMWG high-risk definition.

Ajay K Nooka, MD, MPH: Exelixis - Honoraria; Perceptive Informatics LLC - Honoraria; Ascentage - Honoraria; ONK therapeutics - Honoraria; Sebia - Honoraria; OPNA - Honoraria; Sanofi - Honoraria; AstraZeneca - Honoraria; Premier Research - Honoraria; KITE therapeutics - Honoraria; Pfizer - Honoraria; Cellectar biosciences - Honoraria; Blue Earth Diagnostics - Honoraria; GSK - Honoraria; Janssen - Honoraria; Sanofi - Consultancy (Includes expert testimony); Ascentage - Consultancy (Includes expert testimony); Cellectar biosciences - Consultancy (Includes expert testimony); ONK therapeutics - Consultancy (Includes expert testimony); Exelixis - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); KITE therapeutics - Consultancy (Includes expert testimony); Perceptive Informatics LLC - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Blue Earth Diagnostics - Consultancy (Includes expert testimony); Sebia - Consultancy (Includes expert testimony); Premier Research - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); OPNA - Consultancy (Includes expert testimony)